SeaPRwire
Read More

DeFi Insurance Platform Uno Re Launches Cover Portal

pandora
3 minutes

New York, NY, April 19, 2022 – (SEAPRWire) – Uno Re ( http://unore.io/ ), a decentralized insurance platform, will launch its Cover Portal on April 23, 2022. Accessible through Uno Re’s dApp, the Cover Portal addresses an underemphasized need in DeFi space: easy access to insurance. For the first time, DeFi users can insure their crypto-assets in a few simple steps thanks to Cover Portal’s clear and simple UI. The danger of hacker attacks keeps growing within DeFi space (case study: https://bit.ly/3jYokl7 ) and causing drastic losses for users and protocols alike. The total sum lost to hacks in the first quarter of 2022 is up 695% from Q1 2021’s losses. With both the quantity and severity of attacks on the rise, skepticism surrounding the DeFi space is also growing. One of the leading players in DeFi insurance- Uno Re launched its Cover Portal which aims to grant users easy access to insurance coverage through its user-friendly UI. What is Uno Re’s Cover Portal? Cover Portal is Uno Re’s latest dApp – scanning users’ wallet, detecting insurable assets within as well as staked in staking and farming pools across chains, measuring possible risks using an AI-based algorithm, and allowi...

JCN Newswire
Read More

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer’s Disease and Dementia at the 13th Clinical Trials on Alzheimer’s Disease Conference

ruth
3 minutes

TOKYO, Oct 28, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct a total of 7 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (Development Code: BAN2401), at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference to be held virtually from November 4 to 7, 2020.Regarding lecanemab, Eisai will conduct four oral presentations. The first oral presentation will cover clinical study design and initial screening results of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients. The second oral presentation will cover the latest analysis results on expression of amyloid-related imaging abnormalities-edema (ARIA-E) from the Phase II study (Study 201) conducted on early AD patients. The third oral presentation will cover changes in brain-Abeta amounts and preliminary analysis results on ARIA-E expression as observed in the first 12-month treatment period of the ongoing open-label extension (OLE) study of Study 201. The fourth oral presentation will cover baseline characteristics of currently enrolled subjects in the Phase I...